Hikma Pharmaceuticals PLC Annual Report 2014 NOTES TO THE COMPANY FINANCIAL STATEMENTS continued 46.
FINANCIAL ASSETS Cash and cash equivalents These comprise cash held by the Company and short-term bank deposits with an original maturity of three months or less.
The carrying amount of these assets approximates to their fair value.
FINANCIAL LIABILITIES Other payables The Directors consider that the carrying amount of other payables approximates to their fair value.
SHORT-TERM DEBT Short-term debt mainly represents a one-year syndicated bridge loan of $225 million which was entered into on 7 July 2014.
The bridge loan has been used to finance the acquisition of Bedford Laboratories see Note 23.
DUE TO SUBSIDIARIES AND SISTER COMPANIES 2014 2013 Non-current liabilities $m $m Due to Hikma Pharmaceuticals Limited Jordan 100 Due to Hikma Maple Limited 44 Due to Eurohealth International SARL 3 147 2014 2013 Current liabilities $m $m Due to Hikma Investment Ltd. 15 16 15 16 Amounts due to a sister company of $15 million 2013: $16 million represent the non-interest-bearing loan repayable on demand.
LONG-TERM FINANCIAL DEBTS The Company has a seven-year syndicated term loan of $180 million which was entered into on 27 September 2011.
The loan has an outstanding balance at year end of $64 million with a fair value of $63 million, from which $22 million is due in one year.
Quarterly equal repayments of $6 million commenced on 27 March 2013 18 months after the date of the agreement.
During 2014, a voluntary prepayment of $70 million was made.
The loan has been used to finance the Promopharm acquisition and the Groups general capital expenditure.
FINANCIAL POLICIES FOR RISK MANAGEMENT AND THEIR OBJECTIVES Currency risk Currency risks as defined by IFRS 7 arise on account of financial instruments being denominated in a currency that is not the functional currency and being of a monetary nature.
The following table illustrates financial assets and liabilities for the Company in different currencies: Liabilities Assets 2014 2013 2014 2013 $m $m $m $m British Pound 2 A sensitivity analysis based on a 1% movement in foreign exchange rates has no material impact on the Company results and Company statement of changes in equity.
Further details on how the Company manages the currency risk are given in Note 29.
Interest rate risk: an interest rate sensitivity analysis assumes an instantaneous 100 basis point change in interest rates in all currencies from their levels at 31 December 2014, with all other variables held constant.
Based on the composition of the Company debt and cash portfolio as at31 December 2014, a 1% increase decrease in interest rates would result in an additional interest expense income of $1 million being incurred per year 2013: $nil.
